Can a pill that blocks a brain protein ease Parkinson's without levodopa?

NCT ID NCT07725562

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests an experimental oral medication called VG081821AC for people with early to mid-stage Parkinson's disease. The drug blocks a brain protein called the adenosine A2A receptor, which may improve movement symptoms without using levodopa. About 152 adults in China will be randomly assigned to one of three doses of VG081821AC or a placebo, and researchers will measure changes in motor function after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an oral small-molecule adenosine A2A receptor antagonist called VG081821AC
What this could lead to
If it works, this could offer a new treatment option for people with early to mid-stage Parkinson's who want to delay or avoid starting levodopa.
What could go wrong
This is an early-to-mid-stage trial with only 152 participants, so results may not apply broadly. The drug may cause side effects or fail to improve symptoms better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xuanwu Hospital of Capital Medical University

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.